Tami MD - Vascular Biogenics VP Devel
| VBLTDelisted Stock | USD 0.28 0.01 3.45% |
Insider
Tami MD is VP Devel of Vascular Biogenics
| Age | 53 |
| Phone | 972 8 993 5000 |
| Web | https://www.vblrx.com |
Vascular Biogenics Management Efficiency
The company has return on total asset (ROA) of (0.2912) % which means that it has lost $0.2912 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5952) %, meaning that it created substantial loss on money invested by shareholders. Vascular Biogenics' management efficiency ratios could be used to measure how well Vascular Biogenics manages its routine affairs as well as how well it operates its assets and liabilities.Vascular Biogenics currently holds 564 K in liabilities with Debt to Equity (D/E) ratio of 0.05, which may suggest the company is not taking enough advantage from borrowing. Vascular Biogenics has a current ratio of 3.97, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Vascular Biogenics' use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Joan Brown | Allarity Therapeutics | 70 | |
| MD DrSc | Allarity Therapeutics | 81 | |
| Robert Dudley | Transcode Therapeutics | 73 | |
| Carol Odle | Revelation Biosciences | N/A | |
| Jason Davis | Virax Biolabs Group | 53 | |
| MSc MBA | Inozyme Pharma | 53 | |
| Jaa Roberson | Day One Biopharmaceuticals | N/A | |
| Steen Knudsen | Allarity Therapeutics | 64 | |
| Renato Skerlj | X4 Pharmaceuticals | N/A | |
| Klaus Orlinger | Hookipa Pharma | 47 | |
| Senthil Sundaram | Terns Pharmaceuticals | 46 | |
| Christine MBA | Hookipa Pharma | 59 | |
| Weidong Zhong | Terns Pharmaceuticals | 58 | |
| Liean MS | Acumen Pharmaceuticals | N/A | |
| Karen Cashmere | ZyVersa Therapeutics | 73 | |
| Julie MBA | Day One Biopharmaceuticals | 42 | |
| MS MBA | Inozyme Pharma | 48 | |
| Pablo MD | ZyVersa Therapeutics | N/A | |
| MA MS | Inozyme Pharma | N/A | |
| Mike Preigh | Day One Biopharmaceuticals | N/A | |
| James JD | Allarity Therapeutics | 55 | |
Management Performance
| Return On Equity | -0.6 | |||
| Return On Asset | -0.29 |
Vascular Biogenics Leadership Team
Elected by the shareholders, the Vascular Biogenics' board of directors comprises two types of representatives: Vascular Biogenics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Vascular. The board's role is to monitor Vascular Biogenics' management team and ensure that shareholders' interests are well served. Vascular Biogenics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Vascular Biogenics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Samuel Backenroth, Chief Officer | ||
| Naamit Sher, VP of Devel. and Regulatory | ||
| Yael Cohen, Vice President - Clinical Development | ||
| Erez MBA, Sr Operations | ||
| Eyal Breitbart, Vice President Research | ||
| Deborah Scott, Managing Communications | ||
| Pr MD, CEO Director | ||
| Advocate Horn, G Counsel | ||
| Tami MD, VP Devel |
Vascular Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Vascular Biogenics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.6 | |||
| Return On Asset | -0.29 | |||
| Operating Margin | (33.89) % | |||
| Current Valuation | (10.99 M) | |||
| Shares Outstanding | 77.64 M | |||
| Shares Owned By Insiders | 13.48 % | |||
| Shares Owned By Institutions | 14.00 % | |||
| Number Of Shares Shorted | 250.34 K | |||
| Price To Earning | (9.32) X | |||
| Price To Book | 0.35 X |
Thematic Opportunities
Explore Investment Opportunities
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
Other Consideration for investing in Vascular Stock
If you are still planning to invest in Vascular Biogenics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Vascular Biogenics' history and understand the potential risks before investing.
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Stocks Directory Find actively traded stocks across global markets |